Kalaris Therapeutics, Inc. KLRS 深 沪
等待开盘 08-10 09:30:00 美东时间
4.07
-0.120
-2.86%
华盛通- 最 高4.40
- 今 开4.27
- 成交量 5.88万股
- 最 低 4.02
- 昨 收 4.19
- 总市值 0
- 52周最高 11.88
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 2.14
- 委 比 28.66%
- 总股本 --
- 历史最高 48.96
- 量 比 0
- 振 幅 9.07%
- 历史最低 0.38
- 每 手 1
- 风险率 2.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kalaris Therapeutics Appoints Liisa Bayko CFO
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced
07-20 20:03
Why Is Kalaris Therapeutics Stock Gaining Friday?
Kalaris Therapeutics (NASDAQ: KLRS) stock jumps 18% after releasing expanded Phase 1a data for its AMD treatment, TH103.
07-18 01:31
TD Cowen Initiates Coverage On Kalaris Therapeutics with Buy Rating
TD Cowen analyst Tara Bancroft initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Buy rating.
06-16 00:45
Kalaris Therapeutics CFO Matthew Gall Resigns, Effective April 14
https://www.sec.gov/ix?doc=/Archives/edgar/data/1754068/000119312526151215/d108368d8k.htm
04-11 04:16
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
Kalaris Therapeutics will present at the Noble Capital Markets Virtual Equity Conference on June 5, 2025. The presentation will include a fireside Q&A featuring CEO Andrew Oxtoby and CMO Matthew Feinsod. Kalaris focuses on developing treatments for retinal diseases, including their lead candidate TH103 for neovascular AMD and other conditions.
2025-06-02 12:00
